Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder
Richard E. Greenberg, Peter J. O’Dwyer(University of Pennsylvania), Gary D. Steinberg(Fox Chase Cancer Center), Mitchell H. Bamberger(Fox Chase Cancer Center), Charles Bellingham(Fox Chase Cancer Center), Bruce J. Giantonio(Massachusetts General Hospital), Trevor W. Sweatman(Fox Chase Cancer Center), Robert R. Bahnson(Fox Chase Cancer Center), Mitchell Edson(Fox Chase Cancer Center), Stacy J. Childs(Fox Chase Cancer Center), David P. Wood, Mervyn Israel(Fox Chase Cancer Center)
Cited by 64
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541